基因治疗在心肌缺血再灌注损伤中的研究进展  

Research advancement of gene therapy for the myocardial ischemia and reperfusion injury

作　　者：孙智慧[1] 郑良荣[1] 

机构地区：[1]浙江大学医学院附属第一医院心血管内科,浙江杭州310003

出　　处：《国际内科学杂志》2009年第2期69-73,共5页International Journal of Internal Medicine

基　　金：浙江省科技攻关计划(2006C33010)

摘　　要：通过溶栓和经皮冠状动脉血管成形术达到再灌注是即将发生急性心肌梗死的标准处理措施。尽管缺血区的血流复灌对心肌的挽救具有重要意义,再灌注本身可能导致缺血损伤基础上的进一步心肌损伤。目前对心肌缺血再灌注损伤分子和细胞机制的更深理解以及心血管系统基因操作工具的利用,为基因治疗提供了可能性。为了提高人类血管基因治疗的有效性和安全性,对基因转导臷体,基因递送技术和有效治疗基因的鉴定等方面的基础研究是非常必要的。Reperfusion through thrombolysis or percutaneous coronary angioplasty is standard treatment in impending acute myocardial infarction. Although restoration of blood flow to the isebemic area is beneficial for myocardial salvage, reperfusion itself may lead to accelerated myocardial injury beyond that generated by iscbemia alone. Recent advances in understanding the molecular and cellular mechanisms of myocardial ischemia and reperfusion injury, together with the availability of tools for genetic manipulation of the cardiovascular system, offer possibilities for gene therapy. Further basic research on gene transfer vectors, gene delivery techniques, and identification of effective treatment genes is needed to improve the efficacy and safety of human vascular gene therapy.

关 键 词：缺血再灌注损伤 基因治疗 心肌保护 

分 类 号：R543.2[医药卫生—心血管疾病] Q78[医药卫生—内科学]